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Abstract Human bioaccumulative potential is an impor-
tant element in the risk assessment of chemicals. Due to the
high number of synthetic chemicals, there exists the need to
develop prioritisation strategies. The purpose of this study
was to develop a predictive tool for human bioaccumulation
risk assessment that incorporates not only the chemical
properties of the compounds, but also the processes that
tend to decrease the concentration of the compound such as
metabolisation. We used a generic physiologically based
toxicokinetic model that based on in vitro human liver
metabolism data, minimal renal excretion and a constant
exposure was able to assess the bioaccumulative potential
of a chemical. The approach has been analysed using lit-
erature data on well-known bioaccumulative compounds
and liver metabolism data from the ECVAM database and a
subset of the ToxCast phase I chemical library—in total 94
compounds covering pharmaceuticals, plant protection
products and industrial chemicals. Our results provide fur-
ther evidence that partitioning properties do not allow for a
reliable screening criteria for human chemical hazard. Our
model, based on a 100% intestinal absorption assumption,
suggests that metabolic clearance, plasma protein-binding
properties and renal excretion are the main factors in
determining whether bioaccumulation will occur and its
amount. It is essential that in vitro metabolic clearance tests
with metabolic competent cell lines as well as plasma
protein-binding assays be performed for suspected bioac-
cumulative compounds.
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Introduction
To prevent cases in which the use of a chemical can result
in unacceptable consequences for human health or for the
ecosystems, it is generally agreed that risk analysis has to
be carried out. However, due to the large number of
existing chemicals and, for many of them, the lack of
detailed information on their properties, their fate, their
environmental concentrations and their human exposure
pathways, it is generally accepted that screening approa-
ches are necessary to prioritize and to select chemicals of
concern for whose a more detailed risk characterization and
analysis should be performed (Muir and Howard 2006;
Daginnus et al. 2011). Risk assessment is based on two
aspects: ﬁrstly the hazard of a given chemical, which is
function of its physico-chemical properties, and secondly
its exposure levels to ecosystems and to humans. A com-
parison of exposure levels and safe chemical doses/con-
centrations is then carried out and the risk evaluated. The
chemical hazards of a substance are evaluated according to
its persistence (P) in the environment, long-range transport
potential (LRTP), bioaccumulation (B) characteristics and
toxicity (T) (Klasmeier et al. 2006). Substances identiﬁed
during a screening phase as PBT or vPvB (very persistent,
very bioaccumulative) are normally subjected to a detailed
risk assessment.
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DOI 10.1007/s00204-011-0768-0Bioaccumulation refers to the continuous increase in
the concentration of a chemical in an organism, compared
to the chemical’s concentration in the environmental
media to which the organism is exposed, i.e., air, water,
soil, food, etc. Bioaccumulative potential is an important
element in all exercises of chemical prioritization and in
all existing regulations (US EPA 1998; CEPA 1999;
ECHA 2008). The potential of a chemical to bioaccu-
mulate has to be considered for the assessment of its long-
term effect. Bioaccumulation is the result of mass-balance
processes and may be seen as a competition between the
uptake and depuration/metabolism/excretion rates. Due to
the lack of bioaccumulation data for the majority of
substances, there is a strong interest for the use of pre-
dictive methods. The development of predictive tools is
now encouraged by many international policies, and it is
expected that the use of in silico and reliable in vitro
methods will continuously increase in environmental and
human risk-assessment exercises. Most of the predictive
approaches developed so far, when no experimental data
are available, are mainly based on the calculation of the
lipophility of the substance, sometimes using empirical
correlations between a certain bioconcentration factor
(BCF, commonly deﬁned as the ratio of concentrations of
the chemical in the organism and in water, freely dis-
solved, at equilibrium) or bioaccumulation factor (BAF,
considering also the food, i.e., BAF ¼ BCF  
Qn
i¼1 BMFi,
where BMF is the biomagniﬁcation factor expressed as the
ratio of the concentration in the predator to the concen-
tration in the diet –prey-, and the index i refers to the
trophic position in the food chain) and the octanol–water
partition coefﬁcient (KOW) for a certain organism (Mackay
1982). Even though this approach takes into account the
fact that high hydrophobic compounds tend to bioaccu-
mulate in lipids, it does not consider the processes that
will tend to decrease the concentration of the compounds,
such as excretion, depuration and/or metabolisation pro-
cesses, with the possible scenario of a relatively low
lipophilic compound that is not metabolised or excreted,
i.e., high afﬁnity to certain proteins, and under repeated
exposure will reach higher concentrations inside the
organism. In addition, bioaccumulation potential was
evaluated mainly in ﬁsh (Veith et al. 1979; Van der Oost
et al. 2003; Arnot and Gobas 2003) and aquatic species
(Carafa et al. 2009; Zaldı ´var et al. 2011), with few
attempts to evaluate it in terrestrial food chains (Kelly and
Gobas 2001; Gobas et al. 2003). Furthermore, only very
recently several approaches have been developed to
include also bioaccumulation in humans (Czub and
McLachlan 2004a, b; Undeman et al. 2011).
Bioaccumulation is the result of the conservation of
mass in a living system where a substance that enters the
system either leaves it or accumulates within the system.
However, as mentioned above, the biotransformation has
been poorly taken into account in previous studies.
Whereas several approaches have been developed to con-
sider it in ﬁsh (Arnot et al. 2008), few attempts have been
proposed for human. In a recent paper, McLachlan et al.
(2011), in a theoretical framework, have shown that
chemicals with similar partitioning properties may have a
complete different bioaccumulation potential, being meta-
bolisation and/or excretion the main factors responsible for
this behaviour.
One of the main reasons, for the fact that metabolism
and elimination have not been taken into account when
evaluating bioaccumulation potential, is that these pro-
cesses are difﬁcult to evaluate and quantify. However, due
to the last developments on in vitro and high-throughput
techniques, it is now possible to quantify these aspects and
to integrate them into a mechanistic description of the
kinetic processes that monitor the bioaccumulation.
Therefore, it becomes possible to evaluate quantitatively to
which extent a substance bioaccumulates in humans using
physiologically based pharmacokinetic/toxicokinetic mod-
els (PBPK or PBTK).
A PBTK model consists of a series of mathematical
equations that based on the speciﬁc physiology of an
organism and on the biophysical properties of a substance
are able to describe the absorption, distribution, metabo-
lism and elimination (ADME) of the compound within this
organism (Andersen 1981). The solution of these equations
provides the concentration of the chemical compound and
its metabolites over time in the modelled organs and allows
for a sound mechanistic description of the kinetics pro-
cesses including the kinetics of accumulation.
In this work, we have used a generic PBTK model that,
based on in vitro liver metabolism data, minimal renal
excretion and a chronic exposure, is able to assess the
bioaccumulative potential of a chemical. The approach has
been analysed using literature data for some well-known
bioaccumulative compounds, data from the ECVAM
(European Centre for the Validation of Alternative Meth-
ods) database, and for a subset of the ToxCast phase I
chemical library.
Materials and methods
Selected chemicals
The ﬁnal list is mainly based on the merger of two lists: 55
organic chemicals, mostly drugs and pesticides, which is a
subset selected from the list of an international ICCVAM
validation (2009), and a subset of 35 substances (Rotroff
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123et al. 2010), mostly pesticides, of the ToxCast Phase I
chemical library (http://www.epa.gov/nccttoxcast/chemicals.
html). For the ECVAM database chemicals, liver metabo-
lism and unbounded fraction data were taken from Pelko-
nen et al. (2009) and Rousu et al. (2010), whereas a similar
data for the chemicals in ToxCast phase I have been pub-
lished in Rotroff et al. (2010). When more than one value
was provided, we used the average value. The lists had two
duplicate compounds: diuron and parathion. In this case,
we used Rotroff et al. (2010) data. However, similar results
were obtained. In addition, we had included, subject to the
availability of data in the literature, several compounds:
PCBs, PFOS and DDT (Parham and Portier 1998; Locci-
sano et al. 2011; Yamazaki et al. 2010). The list of selected
chemicals as well as their physico-chemical parameters has
been provided in the Supplementary Material, Table 1. For
the estimation of physico-chemical properties, we used EPI
Suite v4.0 form US EPA (2011) and, for pKa, Simulations
Plus ADMET predictor (2011).
Simulated conditions and BCF prediction
For each substance, a mechanistic physiologically based
toxicokinetic model was developed using a generic popu-
lation-based ADME model (Jamei et al. 2009). The Simcyp
software (Simcyp Limited, Shefﬁeld, UK) in its minimal
version, the portal vein, the systemic circulation and the
liver (Rowland Yeo et al. 2010), was used (see Fig. 1a for a
schematic representation and Supplemental Material, sec-
tion 1 for details on the simulation). The PBTK input data
and the predicted parameters used in the present study have
been provided in the Supplementary Material, Table 1.
One difﬁculty in evaluating the BCF for human is the
multiple sources of exposure. The calculation of the human
bioconcentration factor cannot be as easily deﬁned as the
ratio of the concentration in blood and in water. It has been
suggested that bioaccumulation should refer to an increase
in blood concentration with repeat exposures. The suc-
cessive administrations of small doses induce small ﬂuc-
tuations of the concentration of substrate in the systemic
circulation and, at a coarser time scale, the compound
progressively bioaccumulates, see Fig. 1b. The simulations
were performed until the concentrations reach a steady
state. These values have been used to calculate the human
bioconcentration factors, hBCF, deﬁned as:
hBCF ¼ a
C 
sys
D=T
ð1Þ
where C 
sys (mg/l) is the steady-state blood concentration of
the chemical in the systemic circulation, D (mg) is the dose
and T (h) is the time elapses between two successive
exposures. The ratio D/T mimics a constant ﬂow and may
be seen as the result of a constant exposure scenario. The
parameter a in Eq. 1 is a normalizing factor that leads to a
dimensionless bioconcentration factor. Here, we take
a = VPV/t where VPV is the volume of the portal vein and
t has a unit of time and is set at 1 h.
The time proﬁle of the concentration in the systemic
compartment is recorded, and a ﬁrst-order saturating pro-
cess is used to approximate its global shape. The Simcyp-
computed trajectory is approximated by a transitory regime
characterized by a time constant, ssys, followed by the
saturating regime described by the steady-state value C 
sys.
The numerical value of the couple ðC 
sys;ssysÞ is computed
for all the selected compounds, and the C 
sys value is used to
compute hBCF according to Eq. 1. The time constant ssys
is used to evaluate the bioaccumulation half-life noted Tacc
and deﬁned as Tacc = ssys ln 2. Because we were describ-
ing the time proﬁle of the systemic concentration caused by
successive exposures, the bioaccumulation half-life used
here is different from the biological half-life commonly
Fig. 1 PBTK model and
simulations. a Schematic
representation of the generic
PBTK model used to simulate
perfusion-limited uptake of
compound under a chronic
exposure. b Typical time proﬁle
of the systemic compartment
concentration where the
successive bumps induced by
repeated exposures have been
exempliﬁed. The dotted line is
the trajectory of the averaged-
PBTK model. See
Supplementary Material,
Sections 2 and 3 for more
details
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123used in pharmacokinetic studies that describes the increase
of drug concentration following a single uptake with a ﬁrst-
order kinetic models and refers to the time it takes for the
blood plasma concentration to halve its steady state. It is
also different from the well-known elimination half-life
that is used to describe the decay of a substance.
Characterization of the hBCF
A direct and straightforward estimation of the hBCF based
solely on a limited number of compound characteristics is
highly desirable for prioritization exercises and may pro-
vide an efﬁcient pre-screening criterion for a rapid
assessment. In this sense, we have developed a simpliﬁed
mapping based on two parameters to assess the bioaccu-
mulation potential of compounds. The derivation of the
expression is based on the averaging of the generic Sim-
cyp-PBTK model and provides an analytical approxima-
tion of the hBCF. Comparison with the hBCF obtained
with the complete PBTK model is done.
The proposed measure of hBCF is derived from the
steady state reached by the PBTK model after successive
exposures. To explore other bioaccumulation metrics, we
investigate a possible characterization of the hBCF based
(1) on the bioaccumulation half-time and (2) on the
structure of the PBTK model that describes the toxicoki-
netics of the compound. For the latter, we calculated for
each compound the distance between the actual PBTK
model that describes the toxicokinetic of the compound and
a virtual PBTK model without clearance, i.e., a PBTK
model for which the compound fully bioaccumulates in the
body without biotransformation or excretion. We called
this model the virtual trap PBTK model. The proposed
measure is obtained from the singular value decomposition
of the PBTK matrix that describes the kinetics of the
compound (see Supplementary Material, Section 4). A
comparison of the results obtained using the different
approaches in terms of bioaccumulation potential assess-
ment is done.
Assessment of PBTK model results
To assess the validity of our modelling approach, published
pharmacokinetic data were collected and compared with
our model results (see Supplementary Material, Section 1).
Results and discussion
PBTK model validation
In Table 1, the results of our model for twelve chemicals
were compared with published pharmacokinetic/tox-
icokinetic data and published PBTK model predictions. Our
results agree with the results obtained by Rotroff et al.
(2010) concerning 2,4-dichlorophenoxyacetic acid, oxytet-
racycline dehydrate, triclosan, bisphenol A and parathion.
Our simulated results, 40 h, agree with experimental
data on plasma elimination half-lifes of warfarin for the
two enantiomers: R-warfarin 46 ± 7 h and S-warfarin
Table 1 Comparison of our
model simulations with
literature human data and
published PBTK model results
a for 1 mg kg
-1 day
-1 dose;
b
for 10 mg day
-1 dose;
c for
20 mg day
-1 dose
Compound Css (steady-state concentration) for 1 mg kg
-1 day
-1 dose
(lM)
Present
study
2,4- Dichlorophenoxyacetic
acid
9.05–90.05 44.47
Oxytetracycline dehydrate 0.36 2.31
Triclosan 2–10 2.18
Bisphenol A \0.13 0.31
Parathion 0.17 0.24
Plasma elimination half-life Present study
Thioridazine 26 (h) 87 (days)
Warfarin (R-isomer) 46 ± 7(h)
(S-isomer) 36 ± 13 (h)
40 (h)
DDT 5–8 (years) 2 (years)
PCBs 10–15 (years) 7 (years)
PFOS 2.4–21.7 (years) 2.5 (years)
Cmax (maximum concentration) (lM) Present study
Chlorpyrifos *0.01
a 0.013
Propranolol 0.15
b
0.23
c
0.12
0.24
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12336 ± 13 h, respectively. The prediction of the maximum
plasma concentration for chlorpyrifos and propranolol
hydrochloride was similar to human kinetic studies and
published PBPK model results. In the last case, also the data
on the time at which Cmax was reached are gathered and
compared with the simulation, i.e., 2 h in the two experi-
ments (10 and 20 mg day
-1 oral dose) and 2.1 h in the
simulations. Apart from the well-known persistent com-
pounds such as PCBs, DDT and PFOS were uncertainty on
the estimations (Simcyp could only run for 200 days, and
we extrapolated the values), and the experimental vari-
ability (e.g. for PCB-153, we have found published values
between 5 and 27.5 years) tends to be higher, the main
discrepancy is obtained for thioridazine where the predicted
elimination half-life value is much higher than the experi-
mental one: an elimination half-life that oscillates around
26 h has been reported while we predicted 87 days. This
points out a limitation of our approach due to the fact that
we consider only liver metabolism and minimal renal
excretion, whereas the main excretion route of thioridazine
seems to be through the faeces. A similar limitation holds
for oxytetracycline where the observed overprediction of
the concentration possibly lies in the fact that a 100% oral
absorption has been considered, whereas a low oral bio-
availability has been reported for this compound (Nielsen
and Gyrd-Hansen 1996). However, as stated before, our
main interest is in developing a fast screening procedure to
estimate human bioaccumulation potential for risk assess-
ment and, as a conservative approach, false-positive pre-
dictions are not our main concern.
Estimation of the hBCF
In Table 2, the human bioaccumulation factor is shown for
the top twenty of the selected compounds (a complete table
is provided in the Supplementary Material, Table 2).
Qualitatively, some of the estimations are in agreement
with the results reported in the literature concerning well-
known human bioaccumulative compounds, i.e., PCBs,
PFOS and the DDT (Cho et al. 2011;K a ¨rrman et al. 2006).
Concerning pharmaceuticals, only two compounds appear
at the lower end of the top list: thioridazine, which is an
antipsychotic agent with central nervous system activity,
and warfarin, which is an anticoagulant. There are some
evidence of accumulation of thiroidazine and its metabo-
lites in brain, a factor of ﬁve when compared with plasma
(Svendsen et al. 1988). However, unlike warfarin for which
the PBTK model results were in agreement with published
data (see Table 1), the results for thioridazine should be
subject to caution due to the overestimation of the com-
pound half-life and, therefore, an expected overprediction
of its concentration levels. As stated before, one explana-
tion is that we have not considered the main route of
elimination for this compound.
Table 2 Estimated human bioconcentration factor (hBCF) for the top twenty compounds. The octanol–water partition coefﬁcient and the nature
of the compound are also reported (PPP is for plant protection products)
Compound name CAS number Log KOW hBCF Main category
PFOS 1763-23-1 6.28 926.4 Industrial Chem.
Emamectin 155569-91-8 5.0 325.4 PPP (insecticide)
Buprofezin 69327-76-0 4.3 44.9 PPP (insecticide)
PCB80 33284-52-5 6.6 44.5 Industrial Chem.
PCB77 32598-13-3 6.63 44.5 Industrial Chem.
PCB153 35065-27-1 7.75 44.2 Industrial Chem.
PCB155 33979-03-2 7.55 44.1 Industrial Chem.
PCB136 38411-22-2 7.65 44.1 Industrial Chem.
Fenvalerate 51630-58-1 6.2 20.2 PPP (insecticide)
Bentazone 25057-89-0 2.34 11.1 PPP (pesticide)
DDT 50-29-3 6.91 8.11 PPP (insecticide)
Parathion 56-38-2 3.83 7.05 PPP (insecticide)
Cyprodinil 121552-61-2 4.0 6.73 PPP (fungicide)
Pyraclostrobin 175013-18-0 5.45 5.28 PPP (fungicide)
2,4- Dichlorophenoxy acetic acid 94-75-7 2.81 5.24 PPP (pesticide)
Fipronil 120068-37-3 4.0 2.64 PPP (insecticide)
Thioridazine 50-52-2 5.9 2.64 Pharmaceutical (antipsychotic)
Warfarin 81-81-2 2.7 2.44 Pharmaceutical (anticoagulant)
Bromacil 314-40-9 2.11 2.33 PPP (herbicide)
Fenoxycarb 72490-01-8 4.3 2.33 PPP (insecticide)
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123Two agricultural chemicals appear at the top of the list,
emamectin and buprofezin. The higher values obtained for
both compounds are due to two different reasons: in the
ﬁrst case due to the low clearance rate and in the second
due to the low unbounded fraction value that decreases our
calculated renal clearance. For emamectin, there is some
evidence of low bioaccumulation in aquatic species, with a
BCF of 80 for the whole Bluegill Sunﬁsh (Chukwudebe
et al. 1996), which, therefore, classiﬁes the compound as
nonbioaccumulative. In the same paper, it is also reported
that similar results have been found in mammals (rats and
goats), but the authors refer to unpublished data. The
potential to bioaccumulate predicted by our analysis for
emamectin suggests that further review for this compound
may be warranted.
Comparing to emamectin, a higher BCF value for ﬁsh
has been reported for buprofezin (BCF = 509 whole ﬁsh)
and also for fenvalerate (BCF = 1,664), parathion
(BCF = 97), cypronidil (BCF = 393), pyraclostrobin
(BCF = 706), ﬁpronil (BCF = 202), whereas lower values
have been reported for bentazone (BCF = 21), 2,4-D
(BCF = 3.16) and bromacil (BCF = 3.2), data from EPI
Suite
TM (US EPA 2011) and the Footprint Database (EUP
2009). However, these values are not sufﬁcient to classify
these substances as bioaccumulative. According to the
European Chemicals Agency (ECHA 2008) and previous
legislation, the criteria to be classiﬁed as Bioaccumulative
(B) or very Bioaccumulative (vB) are the following:
BCF[2,000 l kg
-1 and BCF\5,000 l kg
-1? B
BCF[5,000 l kg
-1? vB
Concerning mammal species, there are few data dis-
cussing bioaccumulation potential, and the results obtained
for a particular species cannot be directly extrapolated
to another species. For example, some bioaccumulation
potential from ﬁpronil has been reported in beef cattle,
whereas rapid metabolisation seems to occur in rats (Tingle
et al. 2003). Here, ﬁpronil appears in the top twenty list
suggesting a bioaccumulative potential for human.
Questioning of the hydrophobicity paradigm
The octanol–water partition coefﬁcient has been commonly
used as the main screening criterion for the assessment of
the bioaccumulation potential with the idea that this value
is a surrogate for the tendency of a compound to partition
to tissue lipid. The overwhelming majority of works have
focused on the applicability of this approach for ﬁsh, with
recent approaches considering other properties, such as
size, ionization potential, potential metabolism, etc. How-
ever, it is not clear to which extend a predictive method
based on the octanol–water partition coefﬁcient is relevant
for terrestrial life, as already discussed by Gobas et al.
(2003), and more speciﬁcally for human bioaccumulation
assessment. To analyse these aspects, we have plotted in
Fig. 2a, the logarithm of the predicted human bioconcen-
tration factor, log hBCF, as a function of log KOW. The
relative weak inﬂuence of the octanol–water partition
coefﬁcient is clearly illustrated (r
2 = 0.18), despite a
substantial correlation of the log KOW with the bioaccu-
mulation factors for ﬁsh (Fig. 2b, r
2 = 0.81 for the
experimental values, r
2 = 0.79 for Method 1 EPI Suite
TM
values and r
2 = 0.77 for Method 2 EPI Suite
TM values (US
EPA 2011). Therefore, this approach has a limited domain
of applicability and appears to be inconclusive for human
prediction. The comparison between the log hBCF and the
log BCF obtained from experiments and EPI Suite
TM val-
ues (see Fig. 2c) indicates a strong discrepancy between
human and ﬁsh. Even if a small correlation exists between
the log BCF for ﬁsh and for human (r
2 = 0.22), the bio-
accumulation assessment for human cannot be obtained
from studies on ﬁsh. These results suggest that the deter-
minants for human and ﬁsh bioaccumulation are quite
different, and bioaccumulation potential should be evalu-
ated for humans in chemical risk-assessment reports.
The weak inﬂuence of KOW observed here corroborates
recent studies (Czub and McLachlan 2004a, b; McLachlan
et al. 2011) and strongly encourages the investigation of
new criteria for human bioaccumulation. It has been sug-
gested that the susceptibility to biotransformation is the
principal determinant of bioaccumulation in humans. Even
for aquatic life, the estimation of bioaccumulation from
KOW is valid as far as there is no transformation or deg-
radation of the compound. Recent QSAR modelling
approach has been developed to consider the limitation of
bioaccumulation due to metabolism (Dimitrov et al. 2005).
However, it remains unclear how to incorporate such
adjustment factors and alternative predictive methods are
therefore desirable. Mass-balance models used here offer a
powerful conceptual framework that allows the integration
of the kinetics processes that monitor bioaccumulation
together with a mechanistic understanding of the underly-
ing processes and therefore seem to be more appropriate
for bioaccumulation assessment.
The importance of elimination
To evaluate the role of elimination in the biaccumulative
potential of a substance, we derived an approximation of
the hBCF as a function of the intrinsic hepatic clearance
and the renal excretion (see Supplementary Material, sec-
tion 3, Eq. 6). Figure 3 shows the plot of the logarithm of
the approximated hBCF in the (Log(CLuint), Log(fu)) state
space where CLuint (l h
-1) is the intrinsic metabolic
clearance and fu is the unbound fraction in plasma. Each
colour represents a change of half an order of magnitude of
398 Arch Toxicol (2012) 86:393–403
123the bioaccumulation factor. This simpliﬁed mapping was
generated by running the program for all the possible
combinations of liver clearance values and unbounded
fraction. Recall that the intrinsic clearance accounts for
metabolism and is used to derive the hepatic clearance,
whereas the free fraction in plasma is directly related to the
renal excretion through the minimal excretion model. The
rank previously obtained with the complete model is placed
on the mapping near the corresponding compounds.
The classiﬁcation obtained from this mapping is in line
with the one obtained with the complete PBTK model.
A more detailed comparison is done Fig. 4a where the
hBCF for the different compounds is plotted versus its
Fig. 3 The simpliﬁed mapping. Determination of the human bio-
concentration factor (hBCF) as a function of the unbound intrinsic
hepatic clearance CLuint (l h
-1) and the free fraction in plasma, fu.
The logarithmic scale of hBCF is marked on the boundaries
separating the coloured ﬁelds. The predictions are done using an
approximation of the hBCF value computed with the PBTK model for
the 96 selected compounds. For the sake of comparison, the top
twenty ranking obtained with the complete model is indicated (ﬁlled
white circle). Compounds are represented using the following
labelling: circles, ‘open circle’, are for pharmaceutical compounds,
crosses, ‘multiple sign’, are for plant protection products (insecticide,
pesticide,…) squares, ‘open square’, are for industrial chemicals and
triangles, ‘inverted ﬁlled triangle’, are for natural products (alkaloid,
hormone, …). Compounds without liver clearance, i.e., CLuint = 0,
are arbitrary placed on the map at a log value of -5
Fig. 2 Inﬂuence of partitioning on bioaccumulation. a Plot of the
bioconcentration factor for ﬁsh as a function of the octanol–water
partition coefﬁcient for the selected compounds. Method 1 and
Method 2 refer to predicted values from EPI Suite
TM algorithms and
values depicted with red crosses indicated experimental data. Panels
b and c are plots of the human bioaccumulation factor as a function
of: b the octanol–water partition coefﬁcient and c the bioconcentra-
tion factor for ﬁsh
b
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123approximation. All the points lie on the diagonal except the
points associated to PCBs and PFOS that show a signiﬁcant
difference, but these compounds are still classiﬁed as
bioaccumulative with the two approaches.
The simpliﬁed mapping summarizes the results obtained
for the analysed compounds using Simcyp when placed on
the developed plot using the analytical expression. The
compounds have been divided into several classes: phar-
maceuticals, plant protection products (PPP), industrial
chemicals and natural products. Compounds crossing the
zero line have a bioaccumulative potential. As it can be
observed, pharmaceutical compounds do not tend to bio-
accumulate or have low values. This is expected since they
have been designed to be active and easily degradable.
Conversely, a considerable amount of PPP and industrial
chemicals show some bioaccumulative potential.
The ability to describe the bioaccumulative potential of a
compound through the metabolism combined with the renal
excretion shows that the clearance is the main determinant
factor for human bioaccumulation. We believe that this
approach offers a fast and reliable approach to assess human
bioaccumulative potential in a high-throughput set-up by
performing two in vitro tests: one to calculate the chemical
bindingtoplasmaproteinsusingstandardtechniquessuchas
equilibrium dialysis (Waters et al. 2008), ultraﬁltration
(ZhangandMusson2006)orultracentrifugation(Nakaietal.
2004)andtheothertoestimatetheliverclearance byinvitro
measuring the metabolite formation and/or the substrate
depletion of the compound using human hepatocytes
(Pelkonen et al. 2009; Rotroff et al. 2010).
Alternative assessment of hBCF
The method used above to predict the bioaccumulation
potential of a substance is based on the steady-state reaches
by the corresponding PBTK model. To evaluate to which
extent the time-signature of a compound could also provide
an indication about its bioaccumulative potential, we
compared Fig. 4b the bioconcentration factor as a function
of the bioaccumulation half-ﬁle (Tacc). Compounds that
have a high hBCF value tend to have a high bioaccumu-
lation half-life. A correlation of r
2 = 0.59 is found between
the two logarithmic values. This inter-dependence stems
Fig. 4 A Assessment of the accuracy of the simpliﬁed mapping. The
human bioconcentration factor predicted by the PBTK model is
compared with the prediction given by the simpliﬁed mapping shown
in Fig. 3. An interval of ±0.35 around the identity has been plotted
that could account for the variation experimentally observed on the
replicated measures of BCF. b–c. Alternative characterizations of
human bioaccumulation. Log–log plot of the human bioconcentration
factor as a function of b the bioaccumulation half-life and c the
inverse of the distance to the virtual trap PBTK model, i.e., the PBTK
model without excretion
b
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123from the ability of the bioaccumulation half-time to
describe the elimination kinetics, speciﬁcally for com-
pounds with a slow kinetics where the toxicokinetics is
essentially described with one compartment. For instance,
for PFOS, we found a bioaccumulation half-life of
2.5 years which is identical to the elimination half-life
predicted by our model. Warfarin has a shorter bioaccu-
mulation half-life, 42 h, which is still quite similar to the
predicted value for the elimination half-life, 40 h.
The comparison of the top twenty hBCF-based ranking
previously obtained with the one based on the bioaccumu-
latiomhalf-lifeshowsanoverlapforsixteencompounds(see
Supplementary Material, Table 3). However, despite the
bioaccumulation potential is entangled with the bioaccu-
mulationhalf-life,thetimeproﬁleofthecompoundobtained
with repeated exposures only provides a partial criteria and
does not allow a reliable identiﬁcation of bioaccumulative
chemicals since a difference of several orders of magnitude
for hBCF values is observed for compounds with close
bioaccumulation half-life. Moreover, etoxazole, isoxaben,
zoxamideandamitriptylineappearinthe toptwentyranking
based on Tacc, whereas their hBCF values are, respectively,
1.6, 1.22, 0.93 and 0.70 which rank them at the place 23, 25,
29 and 34. Conversely, some compounds with a high bio-
accumulation potential do not appear at the top of the list
based on bioaccumulation half-life.
The bioaccumulation half-life is a synthetic measure of
the time-evolution of a compound that tends to reduce the
dynamic to a single compartment model. However, the
actual toxicokinetics of the selected compounds is not likely
to be consistent with a ﬁrst-order kinetic model. We found
that a preferable metric is based on the distance of the actual
PBTK model to the virtual trap PBTK model. A correlation
of r
2 = 0.71 between the hBCF (log) and proposed distance
(log) is found (see Fig. 4c). Using the ranking based on this
measure, the top twenty list is almost completely recovered,
and the two rankings only differ from two compounds (see
SupplementaryMaterial,Table 4).Fenoxycarbandwarfarin
donotappearinthisnewrankingbutarelocatedattheendof
the hBCF-based list. Conversely, etoxazole (pesticide) and
isoxaben (herbicide) are at position 12 and 20, whereas
theyareranked23and25accordingtotheirhBCF.Notethat
ahighbioaccumulationpotential (for ﬁsh)hasbeen reported
for etoxazole, whereas a low bioaccumulative potential in
mammals has been suggested for isoxaben (NPIC 2011).
Thistheoreticalmeasureprovidesareliablecharacterization
of the bioaccumulation potential of a substance that has
the twofold advantage of being independent of the exposure
and being obtained efﬁciently with a well-established algo-
rithm on matrix computation without requiring the compu-
tation of all the time-dependent concentrations of the
PBTK models. Therefore, this approach could provide a
valuable tool for fast screening in large databases.
Conclusions
The vast majority of the approaches to predict the bioac-
cumulation potential consider only the partitioning of the
chemical and not the biotransformation potential of the
organism. The results obtained in this study suggest that it is
possible to have a pre-assessment of the human potential
bioaccumulation by performing two in vitro tests: one to
calculate the chemical binding to plasma proteins and the
other to estimate the liver clearance by in vitro measuring
the metabolite formation and/or the substrate depletion of
the compound using human hepatocytes. Both types of tests
are suited to high-throughput analysis and therefore can be
used for screening purposes for the prioritisation of new
compounds. However, there are several aspects that should
be considered carefully in this approach. First, it is assumed
that the in vitro measurements adequately describe the in
vivo activity. Second, the experimental conditions in the in
vitro tests should have been properly selected, e.g., com-
pounds concentration low enough to avoid saturation when
measuring substrate depletion. Third, concerning the in
vitro clearance, it is assumed that there is no further bio-
transformation in the gastrointestinal track and, in addition,
metabolism occurs only in the liver. Normally, all these
assumptions are conservative, and therefore, it is more
probably to obtain false positives than false negatives as it
can be observed in the compounds that deviate in the
comparison between experimental data and predictions.
Finally, there is the need to develop sensitive throughput
analytical techniques that can allow a better understanding
of the kinetics aspects in in vitro experiments. This would
also help in determining a general procedure for performing
in vitro–in vivo extrapolation (IVIVE) and being able to
move from concentration to dose response without the use
of animal experiments (Adler et al. 2011). Our research is
continuing along these lines.
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